We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
Read MoreHide Full Article
Fate Therapeutics (FATE - Free Report) recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis.
The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.
FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.
The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.
FATE's Price Performance
Year to date, shares of Fate Therapeutics have plunged 44% compared with the industry’s 9% decline.
Image Source: Zacks Investment Research
FATE's Ongoing Development Activities With FT819
FT819 is currently in early-stage development for the treatment of SLE. The company has initiated dose expansion in up to 10 patients at 360 million cells, based on clinical data from the first three patients treated with FT819 in the ongoing phase I study.
The dose expansion stage will evaluate the safety and efficacy of a fludarabine (flu)-free conditioning regimen, consisting of either bendamustine or cyclophosphamide alone, followed by a single dose of FT819.
Fate Therapeutics is also assessing the safety, pharmacokinetics, and anti-B cell activity of FT819 at 900 million cells in dose escalation. It presented data from the first three patients at the American Society of Hematology Annual Meeting. As of the data cutoff date of Dec. 4, 2024, FATE did not observe dose-limiting toxicities or any event of any grade of cytokine release syndrome, immune effector-cell associated neurotoxicity syndrome or graft-versus-host disease.
Additional data from the same is expected to be presented at a medical conference later in 2025.
Fate Therapeutics reached an agreement with the FDA to allow for the clinical investigation of additional B cell-mediated autoimmune diseases under the current phase I clinical study of FT819 in December 2024.
FATE's Zacks Rank & Stocks to Consider
Fate Therapeutics currently carries a Zacks Rank #3 (Hold).
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share (EPS) for 2025 have increased from $22.11 to $23.33. During the same time, the EPS estimate for 2026 has increased from $23.23 to $23.35. Year to date, shares of JAZZ have lost 17.4%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s EPS for 2025 have increased from $5.40 to $7.00. During the same time, the figure for 2026 has increased from $9.15 to $10.84. Year to date, shares of KRYS have gained 7.8%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.
In the past 60 days, estimates for ADMA Biologics’ EPS have increased from 69 cents to 71 cents for 2025. During the same time, the EPS estimate for 2026 has increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 21.9%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag
Fate Therapeutics (FATE - Free Report) recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis.
The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.
FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.
The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.
FATE's Price Performance
Year to date, shares of Fate Therapeutics have plunged 44% compared with the industry’s 9% decline.
Image Source: Zacks Investment Research
FATE's Ongoing Development Activities With FT819
FT819 is currently in early-stage development for the treatment of SLE. The company has initiated dose expansion in up to 10 patients at 360 million cells, based on clinical data from the first three patients treated with FT819 in the ongoing phase I study.
The dose expansion stage will evaluate the safety and efficacy of a fludarabine (flu)-free conditioning regimen, consisting of either bendamustine or cyclophosphamide alone, followed by a single dose of FT819.
Fate Therapeutics is also assessing the safety, pharmacokinetics, and anti-B cell activity of FT819 at 900 million cells in dose escalation. It presented data from the first three patients at the American Society of Hematology Annual Meeting. As of the data cutoff date of Dec. 4, 2024, FATE did not observe dose-limiting toxicities or any event of any grade of cytokine release syndrome, immune effector-cell associated neurotoxicity syndrome or graft-versus-host disease.
Additional data from the same is expected to be presented at a medical conference later in 2025.
Fate Therapeutics reached an agreement with the FDA to allow for the clinical investigation of additional B cell-mediated autoimmune diseases under the current phase I clinical study of FT819 in December 2024.
FATE's Zacks Rank & Stocks to Consider
Fate Therapeutics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Jazz Pharmaceuticals, Inc. (JAZZ - Free Report) , Krystal Biotech, Inc. (KRYS - Free Report) and ADMA Biologics, Inc. (ADMA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Jazz Pharmaceuticals’ earnings per share (EPS) for 2025 have increased from $22.11 to $23.33. During the same time, the EPS estimate for 2026 has increased from $23.23 to $23.35. Year to date, shares of JAZZ have lost 17.4%.
JAZZ’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.20%.
In the past 60 days, estimates for Krystal Biotech’s EPS for 2025 have increased from $5.40 to $7.00. During the same time, the figure for 2026 has increased from $9.15 to $10.84. Year to date, shares of KRYS have gained 7.8%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 3.29%.
In the past 60 days, estimates for ADMA Biologics’ EPS have increased from 69 cents to 71 cents for 2025. During the same time, the EPS estimate for 2026 has increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 21.9%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.